← Search & browse all drugs
NERVOUS SYSTEM › ANTI-PARKINSON DRUGS › OTHER ANTIPARKINSON DRUGS › Other antiparkinson drugs
istradefylline
N04CX01
Forms & Strengths
- Oral tablets: 20 mg
- Oral tablets: 40 mg
Adult Dosing
- Recommended dose: 20 mg orally once daily
- Max dose: 40 mg orally once daily
- Used as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing OFF episodes
Mechanism of Action
- Selective adenosine A2A receptor antagonist
- Reduces inhibitory control of the indirect striatopallidal pathway, improving motor function in Parkinson's disease
Contraindications
- Hypersensitivity to istradefylline or any of its excipients
Adverse Reactions
- Dyskinesia
- Dizziness
- Constipation
- Nausea
- Hallucinations
- Insomnia
Drug Interactions
- Strong CYP3A4 inducers (e.g., rifampin): decrease istradefylline exposure, avoid coadministration
- Strong CYP3A4 inhibitors: may increase istradefylline exposure, monitor for adverse reactions
- Smoking (CYP1A1 inducer): may reduce istradefylline plasma concentrations
Curated Content: Needs Vetting Before Put to Clinical Use